Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort

Table 1 P-values computed to compare the effectiveness of b/tsDMARDs in the propensity score-matched groups

Month	DAS28-CRP						CDAI						HAQ
Month	Baseline	1	2	3	6	12	Baseline	1	2	3	6	12	Baseline	1	2	3	6	12
Naïve
TNFi (n = 84) vs CTLA4-Ig (n = 84)	0.8895	0.0009	0.0379	0.2770	0.0644	0.1696	0.9738	0.0012	0.0241	0.2069	0.0522	0.0734	0.9555	0.2426	0.3540	0.6164	0.0995	0.2158
IL6Ri (n = 42) vs CTLA4-Ig (n = 42)	0.3924	0.0052	0.0006	0.0581	0.0017	0.0002	0.4478	0.1712	0.0377	0.4847	0.0339	0.0021	0.5205	0.1566	0.1634	0.9074	0.0684	0.0855
Switch
TNFi (n = 66) vs CTLA4-Ig (n = 66)	0.7118	0.3973	0.7034	0.8598	0.7530	0.5893	0.9324	0.8345	0.5103	0.4629	0.6256	0.9206	0.6335	0.3683	0.1135	0.3937	0.3156	0.2418
IL6Ri (n = 65) vs CTLA4-Ig (n = 65)	0.6384	0.1762	0.9128	0.4938	0.9962	0.2088	0.8586	0.5670	0.1929	0.2623	0.2064	0.9789	0.5369	0.2064	0.1017	0.3292	0.0777	0.1196
JAKi (n = 49) vs CTLA4-Ig (n = 49)	0.8015	0.3209	0.4526	0.7115	0.6972	0.1140	0.9185	0.9117	0.7453	0.3853	0.7996	0.6086	0.3997	0.5394	0.4940	0.9882	0.2413	0.2345

TNFi TNF inhibitors, IL6Ri IL-6 receptor inhibitors, CTLA4-Ig abatacept, JAKi Janus kinase inhibitors, DAS28-CRP Disease Activity Score 28-C-reactive protein, CDAI Clinical Disease Activity Index, HAQ Health Assessment Questionnaire Disability Index

ISSN: 1478-6362